2013-2023年江苏省利福平耐药结核病防治效果分析  

Rifampicin-resistant tuberculosis prevention and control in Jiangsu Province from 2013 to 2023

作　　者：丁慧 于全骥 丁晓艳[1] 邵燕[1] 卢鹏 李忠奇 竺丽梅[1] 刘巧[1] Ding Hui;Yu Quanji;Ding Xiaoyan;Shao Yan;Lu Peng;Li Zhongqi;Zhu Limei;Liu Qiao(Department of Chronic Communicable Disease Control and Prevention,Jiangsu Provincial Center for Disease Control and Prevention,Nanjing 210009,China)

机构地区：[1]江苏省疾病预防控制中心慢性传染病防制所,南京210009

出　　处：《中华流行病学杂志》2025年第4期655-661,共7页Chinese Journal of Epidemiology

基　　金：江苏省卫生健康委员会科研重点项目(ZDA2020022);江苏省“十四五”流行病学重点学科(ZDXK202250)。

摘　　要：目的了解江苏省2013-2023年利福平耐药结核病的发现、纳入治疗和转归变化趋势,评估耐药结核病防治政策和措施实施效果,为更好地控制耐药结核病提供依据。方法从结核病信息管理系统获取2013-2023年江苏省利福平耐药结核病筛查、诊断、治疗和转归相关数据和指标,采用Joinpoint回归方法进行变化趋势分析,计算年变化百分比(APC)和平均年变化百分比(AAPC),并进行相关政策和措施实施前后的对比分析。结果2013-2023年江苏省利福平耐药结核病患者数呈单调上升趋势(APC=AAPC=1.45%,P=0.035)。结核病新患者耐药筛查率、高危人群耐药筛查率和分子生物学耐药检测比例总体呈上升趋势,且均于2018年出现转折点。利福平耐药结核病患者纳入治疗率于2020年出现转折点,2013-2020年呈显著上升趋势(APC=12.91%,P=0.008)。利福平耐药结核病患者成功治疗率变化趋势在2020年出现转折点,2020-2023年呈显著上升趋势(APC=9.94%,P=0.004)。结论2013-2023年江苏省利福平耐药结核病防治工作取得重大进步,相关政策和措施实施后效果显著。Objective To investigate the trends in detection,treatment,and outcomes of rifampicin-resistant tuberculosis(TB)in Jiangsu Province from 2013 to 2023,assess the effectiveness of control policies and measures for drug-resistant TB,and provide evidence for better control of drug-resistant TB.Methods Data and indicators related to the screening,diagnosis,treatment,and outcomes of rifampicin-resistant TB in Jiangsu Province from 2013 to 2023 were obtained from the Tuberculosis Management Information System.The Joinpoint regression method was employed to analyze the trends over this period,and annual percent change(APC)and average annual percent change(AAPC)were calculated.A comparative analysis was also conducted to evaluate the changes before and after implementing relevant policies and measures.Results From 2013 to 2023,the number of registered rifampicin-resistant TB patients in Jiangsu Province showed a consistent upward trend(APC=AAPC=1.45%,P=0.035).The screening rates for drug resistance among new TB patients in high-risk groups and the proportion of molecular biological testing for drug resistance all exhibited increasing trends,with a notable turning point occurring in 2018.The trend of the treatment enrollment rate for rifampicin-resistant TB patients experienced a significant shift in 2020,showing a marked increase from 2013 to 2020(APC=12.91%,P=0.008).The treatment success rate of rifampicin-resistant TB patients also showed a significant upward trend after a turning point in 2020(APC=9.94%,P=0.004).Conclusion From 2013 to 2023,significant progress was seen in preventing and treating rifampicin-resistant TB in Jiangsu Province,with relevant policies and measures proving to be highly effective.

关 键 词：结核病 耐药 利福平 Joinpoint回归 防治效果 

分 类 号：R52[医药卫生—内科学]